Member Info for Timster

Mandatory whooping and a hollering when an RNS is released.

30 staff , 1 drug in clinical trial.

Eli lilly paid $1.4 billion for point, including a pre|CISION license for radiotherapy.

8 billion for us though sometimes in the next 2 weeks.

Never fails, fantastic news for Avacta Hurstbot

H2 LDA

Sorry, yes, Lilly buyout for billions tomorrow, watch the bid!

Bit of an on one to build up with a big announcement really. There's always been a pipeline available on the website to peruse.

Also anything in the pipeline will take many years to come to fruition so hardly going to cause a massive rush to buy shares

Avacta share holders love a guessing game though. My guess would be there might be some heavy hitters helping to advance the pipeline or there's no point making a fuss.

I know!! Only 143 shopping days till Christmas.

7 weeks, sorry can't count.

8 weeks tomorrow for 3rd cohort.

If all has gone well then news should be close, either completion or a new cohort.

Hates a strong word, but for someone who has relentlessly trolled a company developing cancer therapies for years it's probably fair.

WhATs yOUr gAMe PL25?

Well done though, you did say that, I do apologise.

That is a good spot! where was it?

It has been discussed before but only that Avacta would probably be aware.

Fantastic news!!

Avacta also announces the creation of a Scientific Advisory Board to provide expert insight and guidance on the ongoing clinical development of AVA6000 and the pipeline, including the pre|CISION™ platform. The Board will be chaired by William D. Tap MD, Chief of the Sarcoma Oncology Service at the Memorial Sloan Kettering Cancer Center in New York City. Dr. Tap will be joined by several colleagues in both the UK and US including:

· Robin Jones, MBBS, MRCPD, MD, Professor and Group Leader in Sarcoma Clinical Trials at The Institute of Cancer Research and the Royal Marsden Hospital in London.

· Lee Cranmer, MD, PhD, Head of Sarcoma Oncology at the University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington.

· Robert Metcalf, MBChB MRCP PhD, Clinician Scientist in Experimental Cancer Medicine and Honorary Consultant in Head and Neck Cancer Oncology and Salivary Gland Cancer Expert at the Christie NHS Foundation Trust, Manchester.

· Alan Ho, MD, PhD, Clinician-Scientist and translational clinical researcher on the head/neck medical oncology service at Memorial Sloan Kettering Cancer Center, New York City.

· Andrea Napolitano, M.D., PhD. Consultant Oncologist and Experimental Therapeutics Expert at the Institute for Cancer Research and Royal Marsden Hospital, London.

· Anthony Yu, MD, MS, Clinical Onco-Cardiologist specializing in the management of cardio-toxicities of approved and experimental therapeutics, Memorial Sloan Kettering Cancer Center, New York City.

Makes you wonder why these oncology "nobodies" want anything to do with Avacta.

"Thorno in the bumo"

Whatever floats your boat watching 😊

Knew that would trigger green box eggy.

Was one of his fud angles back in the day.

Come on Alan, stop messing about!

Almost 2025 after all LDA...

Fantastic news with Avacta being very active in the CAR T space.

"More evidence of why the market is getting excited about AVA6000 and precision Medicine."

Is it?